Source:http://linkedlifedata.com/resource/pubmed/id/11355304
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2001-5-17
|
| pubmed:abstractText |
Cyclin E and p27Kip1 are co-regulators of the G1- to S-phase transition and closely related to tumor behavior. The purpose of this study was to examine expression of cyclin E and p27Kip1 in astrocytomas and to evaluate the relationships between expression of these cell-cycle regulators and prognosis of patients with astrocytoma. Tissue samples from 130 astrocytomas (WHO grade 1 n = 5, grade 2 n = 23, grade 3 n = 64, grade 4 n = 38) were examined immunohistochemically for cyclin E and p27Kip1 expression. Patient charts were reviewed for clinical presentation, and survival was followed. The cyclin E labeling index (LI) tended to increase with tumor grade (Kruskal-Wallis, P = 0.0104). For patients with primary astrocytomas, the 50% survival times for the low cyclin E LI (< 5%) group and the high cyclin E LI (> or = 5%) group were 53.7 months and 19.8 months. In combined analysis of cyclin E and p27Kip1 expression, the low cyclin E/high p27Kip1 LI (> or = 50%) group had the best survival (50% survival time: 103.2 months), the low cyclin E/low p27Kip1 LI (> or = 50%) and the high cyclin E/high p27Kip1 LI groups moderate survival (24.1 and 27.5 months), and the high cyclin E/low p27Kip1 LI group the worst survival (13.1 months). Multivariate analysis identified the combined factor, high cyclin E/low p27Kip1, as a novel independent prognostic factor for survival time (P = 0.0037, relative risk = 2.4). This study suggested that combined analysis of cyclin E and p27Kip1 expression was considered to be potentially useful in predicting the prognosis of patients with astrocytoma.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cell Cycle Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin E,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Nerve Tissue Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0001-6322
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
101
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
334-40
|
| pubmed:dateRevised |
2007-11-9
|
| pubmed:meshHeading |
pubmed-meshheading:11355304-Adolescent,
pubmed-meshheading:11355304-Adult,
pubmed-meshheading:11355304-Aged,
pubmed-meshheading:11355304-Aged, 80 and over,
pubmed-meshheading:11355304-Astrocytoma,
pubmed-meshheading:11355304-Brain Neoplasms,
pubmed-meshheading:11355304-Cell Cycle Proteins,
pubmed-meshheading:11355304-Child,
pubmed-meshheading:11355304-Child, Preschool,
pubmed-meshheading:11355304-Cyclin E,
pubmed-meshheading:11355304-Cyclin-Dependent Kinase Inhibitor p27,
pubmed-meshheading:11355304-Female,
pubmed-meshheading:11355304-Follow-Up Studies,
pubmed-meshheading:11355304-Gene Expression Profiling,
pubmed-meshheading:11355304-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:11355304-Glioblastoma,
pubmed-meshheading:11355304-Humans,
pubmed-meshheading:11355304-Infant,
pubmed-meshheading:11355304-Infant, Newborn,
pubmed-meshheading:11355304-Japan,
pubmed-meshheading:11355304-Life Tables,
pubmed-meshheading:11355304-Male,
pubmed-meshheading:11355304-Middle Aged,
pubmed-meshheading:11355304-Neoplasm Proteins,
pubmed-meshheading:11355304-Nerve Tissue Proteins,
pubmed-meshheading:11355304-Prognosis,
pubmed-meshheading:11355304-Survival Analysis,
pubmed-meshheading:11355304-Tumor Suppressor Proteins
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
High cyclin E/low p27Kip1 expression is associated with poor prognosis in astrocytomas.
|
| pubmed:affiliation |
Department of Neurological Surgery, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. ttamiya@med.okayama-u.ac.jp
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|